EGFR L858R突变合并EGFR 20外显子插入突变肺腺癌1例报告并文献复习
EGFR L858R Mutation Combined with EGFR Exon 20 Insertion Mutation in Lung Adenocarcinoma: A Case Report and Literature Review
摘要: 尽管表皮生长因子受体(Epidermal Growth Factor Receptor, EGFR)——酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)极大地改善了EGFR突变患者的疗效及预后，但对于EGFR 20外显子插入突变疗效差，患者生存期短、预后差。本文结合文献回顾报道1例EGFR L858R突变合并EGFR 20外显子插入突变的肺腺癌患者，应用吉非替尼治疗后疗效不佳，接受阿法替尼联合化疗疾病得到良好控制，提示阿法替尼联合化疗对合并EGFR 20外显子插入突变的肺腺癌患者有不错的疗效，为阿法替尼联合化疗治疗EGFR L858R突变合并EGFR 20外显子插入突变的肺腺癌患者提供临床依据。
Abstract: Although Epidermal Growth Factor Receptor (EGFR)—Tyrosine kinase inhibitor (TKI) has greatly improved the efficacy and prognosis of patients with EGFR mutations, EGFR exon 20 insertion mutation has poor efficacy, short survival and poor prognosis. This article combined literature review to report a case of lung adenocarcinoma with EGFR L858R mutation combined with EGFR exon 20 insertion mutation. Gefitinib was not effective after treatment, and the disease was well controlled after receiving afatinib combined with chemotherapy, suggesting that afatinib combined with chemotherapy has a good effect on lung adenocarcinoma patients with EGFR exon 20 insertion mutation. It provides clinical evidence for afatinib combined with chemotherapy to treat lung adenocarcinoma patients with EGFR L858R mutation and EGFR exon 20 insertion mutation.
文章引用：朱文婷, 陈衍. EGFR L858R突变合并EGFR 20外显子插入突变肺腺癌1例报告并文献复习[J]. 临床医学进展, 2021, 11(11): 5358-5363. https://doi.org/10.12677/ACM.2021.1111792

参考文献

[1] Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132.
[Google Scholar] [CrossRef] [PubMed]
[2] Midha, A., Dearden, S. and McCormack, R. (2015) EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: A Systematic Review and Global Map by Ethnicity (mutMapII). American Journal of Cancer Research, 5, 2892-2911.
[3] Oxnard, G.R., Lo, P.C., Nishino, M., Dahlberg, S.E., Lindeman, N.I., Butaney, M., et al. (2013) Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions. Journal of Thoracic Oncology, 8, 179-184.
[Google Scholar] [CrossRef] 
[4] Riess, J.W., Gandara, D.R., Frampton, G.M., Madison, R., Peled, N., Bufill, J.A., et al. (2018) Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Journal of Thoracic Oncology, 13, 1560-1568.
[Google Scholar] [CrossRef] [PubMed]
[5] Cardona, A.F., Rojas, L., Zatarain-Barrón, Z.L., Freitas, H.C., Granados, S.T., Castillo, O., et al. (2018) EGFR Exon 20 Insertion in Lung Adenocarcinomas among Hispanics (Geno1.2-CLICaP). Lung Cancer, 125, 265-272.
[Google Scholar] [CrossRef] [PubMed]
[6] Arcila, M.E., Nafa, K., Chaft, J.E., Rekhtman, N., Lau, C., Reva, B.A., et al. (2013) EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. Molecular Cancer Therapeutics, 12, 220-229.
[Google Scholar] [CrossRef] 
[7] Yang, G., Li, J., Xu, H., Yang, Y., Yang, L., Xu, F., et al. (2020) EGFR Exon 20 Insertion Mutations in Chinese Advanced Non-Small Cell Lung Cancer Patients: Molecular Heterogeneity and Treatment Outcome from Nationwide Real-World Study. Lung Cancer, 145, 186-194.
[Google Scholar] [CrossRef] [PubMed]
[8] Leduc, C., Merlio, J.P., Besse, B., Blons, H., Debieuvre, D., Bringuier, P.P., et al. (2017) Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) Program. Annals of Oncology, 28, 2715-2724.
[Google Scholar] [CrossRef] [PubMed]
[9] Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., et al. (2014) Rare EGFR Exon 18 and Exon 20 Mutations in Non-Small-Cell Lung Cancer on 10117 Patients: A Multicentre Observational Study by the French ERMETIC-IFCT Network. Annals of Oncology, 25, 126-131.
[Google Scholar] [CrossRef] [PubMed]
[10] Yasuda, H., Park, E., Yun, C.H., Sng, N.J., Lucena-Araujo, A.R., Yeo, W.L., et al. (2013) Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Science Translational Medicine, 5, Article No. 216ra177.
[Google Scholar] [CrossRef] [PubMed]
[11] Yang, M., Xu, X., Cai, J., Ning, J., Wery, J.P. and Li, Q.-X. (2016) NSCLC Harboring EGFR Exon-20 Insertions after the Regulatory C-Helix of Kinase Domain Responds Poorly to Known EGFR Inhibitors. International Journal of Cancer, 139, 171-176.
[Google Scholar] [CrossRef] [PubMed]
[12] Robichaux, J.P., Elamin, Y.Y., Tan, Z., Carter, B.W., Zhang, S., Liu, S., et al. (2018) Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20-Selective Kinase Inhibitor in Non-Small Cell Lung Cancer. Nature Medicine, 24, 638-646.
[Google Scholar] [CrossRef] [PubMed]
[13] Tu, H.Y., Ke, E.E., Yang, J.J., Sun, Y.L., Yan, H.H., Zheng, M.Y., et al. (2017) A Comprehensive Review of Uncommon EGFR Mutations in Patients with Non-Small Cell Lung Cancer. Lung Cancer, 114, 96-102.
[Google Scholar] [CrossRef] [PubMed]
[14] Yang, J.C., Sequist, L.V., Geater, S.L., Tsai, C.M., Mok, T.S., Schuler, M., et al. (2015) Clinical Activity of Afatinib in Patients with Advanced Non-Small-Cell Lung Cancer Harbouring Uncommon EGFR Mutations: A Combined Post-Hoc Analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncology, 16, 830-838.
[Google Scholar] [CrossRef] 
[15] Kuiper, J.L., Hashemi, S.M.S., Thunnissen, E., Snijders, P.J., Grünberg, K., Bloemena, E., et al. (2016) Non-Classic EGFR Mutations in a Cohort of Dutch EGFR-Mutated NSCLC Patients and Outcomes Following EGFR-TKI Treatment. British Journal of Cancer, 115, 1504-1512.
[Google Scholar] [CrossRef] [PubMed]
[16] Naidoo J, Sima CS, Rodriguez K, Busby, N., Nafa, K., Ladanyi, M., et al. (2015) Epidermal Growth Factor Receptor Exon 20 Insertions in Advanced Lung Adenocarcinomas: Clinical Outcomes and Response to Erlotinib. Cancer, 121, 3212-3220.
[Google Scholar] [CrossRef] [PubMed]
[17] Wu, J.Y., Yu, C.J. and Shih, J.Y. (2019) Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer with Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 20, e620-e630.
[Google Scholar] [CrossRef] [PubMed]
[18] Horn, L., Lin, H.M., Padda, S.K., Aggarwal, C., Elizabeth McCoach, C., Zhu, Y., et al. (2020) Indirect Comparison of TAK-788 VS. Real-World Data Outcomes In Refractory Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertions. Journal of Clinical Oncology, 38, 9580.
[Google Scholar] [CrossRef] 
[19] Sabari, J.K., Shu, C.A., Park, K., Leighl, N., Mitchell, P., Kim, S., Lee, J., et al. (2021) Amivantamab in Post-Platinum EGFR Exon 20 Insertion Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 16, S108-S109.
[Google Scholar] [CrossRef] 

为你推荐